Treatment of recurrent gioblastoma with perillyl alcohol
AssigneeNeOnc Technologies, Inc.
InventorThomas C. CHEN
Life of this patent
Estimating the term…
Abstract
The present invention provides an intranasal glioblastoma therapy with purified perillyl alcohol. Patients with recurrent glioblastoma when treated with perillyl alcohol purified by the disclosed methods showed improved survival when compared to historical controls. Glioblastoma patients with an isocitrate dehydrogenase 1 (IDH1)-mutation showed improved survival when compared with wild-type IDH patients.
Claims15
A method of treating a tumor of the nervous system in a patient, wherein the patient has a mutated isocitrate dehydrogenase 1 (IDH1) gene, the method comprising administering to the patient a pharmaceutical composition comprising perillyl alcohol (POH) or a perillyl alcohol carbamate, wherein the perillyl alcohol carbamate is perillyl alcohol covalently bound via a carbamate linking group to a therapeutic agent.
Dependencies are inferred from the claim text.